Comparative analysis of the information reported on labels of medicinal products containing new active substances between Europe and the USA
{{output}}
Introduction: Although notable efforts have been made to harmonise regulatory processes for the approval of new therapeutic drugs by the competent authorities, some discrepancies concerning risk-benefit assessments and regulatory... ...
